The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β
asthma
human airways
human precision-cut lung slice
muscarinic antagonist and β2AR agonist
navafenterol
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
06 01 2023
06 01 2023
Historique:
received:
29
11
2022
revised:
25
12
2022
accepted:
03
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Bronchodilators and anti-inflammatory agents are the mainstream treatments in chronic obstructive and pulmonary disease (COPD) and asthma. The combination of β
Identifiants
pubmed: 36672178
pii: cells12020240
doi: 10.3390/cells12020240
pmc: PMC9856842
pii:
doi:
Substances chimiques
Bronchodilator Agents
0
Muscarinic Antagonists
0
Histamine
820484N8I3
Propranolol
9Y8NXQ24VQ
Receptors, Muscarinic
0
Adrenergic Agonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Allergy Asthma Proc. 2011 Sep-Oct;32(5):359-65
pubmed: 22195688
Pharmacol Ther. 2019 Jan;193:1-19
pubmed: 30081047
Thorax. 2016 Jan;71(1):15-25
pubmed: 26490732
Int J Chron Obstruct Pulmon Dis. 2016 Apr 15;11:785-97
pubmed: 27143870
Pulm Pharmacol Ther. 2017 Oct;46:1-10
pubmed: 28729041
J Med Chem. 2015 Mar 26;58(6):2609-22
pubmed: 25629394
Bioorg Med Chem Lett. 2011 Mar 1;21(5):1354-8
pubmed: 21310610
Am J Respir Crit Care Med. 2019 May 15;199(10):1282-1284
pubmed: 30768909
J Pharmacol Exp Ther. 2019 Jul;370(1):127-136
pubmed: 31085697
Expert Opin Ther Pat. 2012 Nov;22(11):1377-83
pubmed: 22917191